Review spotlights dogs and cats in neuroendocrine oncology
Bottom line
A new review in Frontiers in Veterinary Science, published June 19, 2026, argues that dogs and cats could play a bigger role in neuroendocrine tumor, or NET, research, because these cancers share important biologic and clinical features across species. The authors reviewed PubMed literature through December 2025 and found that companion-animal NETs, especially functional pancreatic, hepatic, and intestinal tumors, mirror many aspects of human disease. At the same time, they say veterinary medicine still lacks the registries, standardized imaging, validated biomarkers, and prospective treatment data needed to fully use these cases in comparative oncology. (frontiersin.org)
Why it matters: For veterinary professionals, the paper is less about a new therapy than a shift in framing: NET cases in dogs and cats shouldn't be seen only as rare curiosities, but also as clinically meaningful patients whose workups, pathology, and outcomes could inform both veterinary care and translational cancer research. The review highlights a familiar gap in practice, too. In human medicine, NET incidence and outcomes are tracked at population scale, while veterinary evidence still comes mostly from case series and pathology reviews, making it harder to benchmark prognosis, compare treatment approaches, or build multicenter studies. That matters if the field wants to move rare endocrine tumors from anecdotal management toward more standardized diagnosis and evidence generation. (frontiersin.org)
What to watch: Whether this review helps spur multicenter reporting frameworks, shared biospecimen efforts, and comparative oncology trials that include naturally occurring NETs in veterinary patients. (frontiersin.org)
Key facts
- Journal
- Frontiers in Veterinary Science
- Publication date
- June 19, 2026
- Study type
- Review
- Literature search
- PubMed through December 2025
- Studies included
- 146
- Main finding
- Dog and cat NETs share key biologic and clinical features with human NETs
- Most documented veterinary NETs
- Functional pancreatic, hepatic, and intestinal tumors
- Main evidence gap
- No registries, standardized imaging, validated biomarkers, or prospective treatment data
A newly published review in Frontiers in Veterinary Science makes the case that neuroendocrine tumors in dogs and cats deserve more attention from both veterinary oncology and translational cancer research. Published on June 19, 2026, the paper concludes that companion-animal NETs recapitulate many key biologic and clinical features of human NETs, particularly in functional pancreatic, hepatic, and intestinal disease, but says the field still lacks the infrastructure needed to translate those similarities into better evidence and care. (frontiersin.org)
That argument lands in a broader comparative oncology moment. The basic premise isn't new: naturally occurring cancers in companion animals have long been viewed as useful translational models because pets share human environments, develop spontaneous disease, and can be evaluated with many of the same imaging and clinical tools. Federal cancer programs have continued to build around that model, including the National Cancer Institute's Comparative Oncology Program, the Comparative Oncology Trials Consortium, and newer canine data and immuno-oncology efforts designed to connect veterinary patients to human drug development. (pmc.ncbi.nlm.nih.gov)
What this review adds is a focused look at NETs, a tumor family that often gets less attention in veterinary comparative oncology than osteosarcoma, lymphoma, or melanoma. The authors searched PubMed from database inception through December 2025, screened the literature without language or study-design restrictions, and included 146 studies in a qualitative synthesis. They compared epidemiology, histopathology, biomarkers, clinical signs, imaging, treatment, and prognosis across humans, dogs, and cats. Their bottom line: veterinary NETs appear biologically relevant, but the evidence base is fragmented. (frontiersin.org)
The paper also underscores how uneven the data landscape remains. In humans, NETs account for roughly 2% of cancers, affect fewer than 200,000 people in the United States, and have shown rising incidence over time, supported by registry-scale datasets. In companion animals, by contrast, formal population-level incidence is largely unavailable, and much of what clinicians know comes from retrospective reports. The review notes that pancreatic NETs are the best documented in dogs, that metastatic disease is often evident at diagnosis in veterinary patients, and that no robust population surveillance system exists to define incidence, breed risk, or survival patterns with confidence. (frontiersin.org)
Outside reaction specific to this paper appears limited so far, which isn't unusual for a narrative review in a niche oncology segment. Still, the broader field has been making a similar case for years. NCI materials describe pet dogs with naturally occurring cancers as useful models for studying toxicity, pharmacokinetics, pharmacodynamics, biomarkers, and treatment response, while comparative oncology reviews in the scientific literature emphasize that shared environment, intact immunity, and spontaneous tumor evolution can make companion animals more informative than induced laboratory models for some questions. In that sense, this NET review is best read as an effort to bring a rare tumor category into an already established translational framework. (ostr.ccr.cancer.gov)
Why it matters: For veterinary professionals, the practical takeaway is that rare endocrine and neuroendocrine cases may have more value than the current evidence system captures. Better case ascertainment, more standardized pathology language, consistent biomarker testing, and clearer imaging and outcome reporting could improve day-to-day patient management while also making these cases usable in multicenter research. That's especially relevant in a field where uncommon tumors can remain clinically silent, present late, or mimic other diseases, and where individual practices may only see scattered cases over time. If veterinary centers can aggregate those cases more systematically, the payoff could be twofold: better care for animal patients, and stronger comparative evidence that informs future diagnostics and therapeutics across species. (frontiersin.org)
What to watch: The next step isn't likely to be a single breakthrough treatment, but infrastructure: harmonized reporting frameworks, prospective multicenter datasets, and inclusion of NET-relevant specimens and clinical annotations in comparative oncology pipelines. If those pieces develop, NETs could become a more visible part of the same translational ecosystem that already supports canine trials, biospecimen repositories, and integrated cancer data resources. (frontiersin.org)